Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Cabaletta Bio (CABA) to $30 from $15 and keeps an Overweight rating on the shares. Auto-CAR-T is showing unprecedented and transformational efficacy in scleroderma, and investors aren’t appreciating how substantial this unmet need is, the analyst says in a research note, adding that bispecifics are also starting to look “good.”